ChromaDex Corporation - Common Stock (NQ:CDXC)

7.870 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For March 6, 2024 ↗

March 06, 2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.

Via Benzinga

Earnings Preview For ChromaDex ↗

March 05, 2024

Via Benzinga

ChromaDex: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

Earnings Outlook For ChromaDex ↗

November 07, 2023

Via Benzinga

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

February 21, 2024

From ChromaDex Corporation

Via Business Wire

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

February 05, 2024

From ChromaDex Corporation

Via Business Wire

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

January 26, 2024

From ChromaDex Corporation

Via Business Wire

Recap: ChromaDex Q1 Earnings ↗

May 10, 2023

Via Benzinga

ChromaDex Earnings Perspective: Return On Capital Employed ↗

March 10, 2023

Via Benzinga

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

December 20, 2023

From ChromaDex Corporation

Via Business Wire

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

November 30, 2023

From ChromaDex Corporation

Via Business Wire

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

November 15, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

November 09, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

November 08, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

November 01, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 31, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

October 26, 2023

From ChromaDex Corporation

Via Business Wire

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

August 24, 2023

From ChromaDex Corporation

Via Business Wire

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

October 02, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

August 09, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

August 08, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series

August 07, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

August 02, 2023

From ChromaDex Corporation

Via Business Wire

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

July 18, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

June 16, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Participate in the LD Micro Invitational XIII

May 30, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

May 11, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Corporation Reports First Quarter 2023 Financial Results

May 10, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

May 02, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

March 08, 2023

From ChromaDex Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.